Evidence Intelligence™
- EvidenceScore™
- 78
- Strong
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 3 estudios
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Tirzepatide improves weight loss and cardiometabolic health
Última actualización 12 de septiembre de 2026
Key finding
Weight (kg) decreased by -23.3 ± 0.3 in early responders and -14.6 ± 0.4 in nonearly responders (p < 0.001).
The study evaluated the effects of Tirzepatide on weight reduction and cardiometabolic risk in individuals with obesity or overweight, showing significant improvements in various health metrics.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
High Risk
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
The study evaluated the effects of Tirzepatide on weight reduction and cardiometabolic risk in individuals with obesity or overweight, showing significant improvements in various health metrics.
Clinical relevance
The findings highlight Tirzepatide's potential as an effective treatment for obesity and related health risks, which is crucial given the rising prevalence of obesity and its associated comorbidities. Effective weight management can lead to improved overall health and reduced healthcare costs, making this medication a valuable option for patients struggling with obesity.
Keep in mind
Limited generalizability due to specific participant characteristics. Potential for unmeasured confounding factors. Short duration of follow-up may not capture long-term effects.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Alexander K, Tina T, Clare JL, et al. Tirzepatide for Weight Reduction and Cardiometabolic Risk Improvement in Individuals with Obesity or Overweight. Diabetes, Obesity & Metabolism. 2026;28(9):8367-8377. doi:10.1111/dom.71009
Efectos Principales
Body weight decreased by -23.3 kg in early responders (p < 0.001).
BMI reduced by -8.7 kg/m² in early responders (p < 0.001).
Waist circumference decreased by -20.6 cm in early responders (p < 0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Tirzepatide and BMI, Body weight, Diastolic blood pressure, and 7 more.
This study contributes evidence to
Primary intervention
Tirzepatide
Primary outcomes
- BMI
- Body weight
- Diastolic blood pressure
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
10
Evidence pairs
10
Relationships
5
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
5
Related topics
10
Evidence pairs
1363
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 10 evidence relationships
- Includes primary outcome data
- Linked to 5 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and HbA1c
Evidencia relacionada
Relación de evidencia
GLP-1 Receptor Agonists and Body Weight
Guardar evidencia
Relación de evidencia
GLP-1 Receptor Agonists and Body Mass Index
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 92
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 13 estudios
Add to Evidence TrackerDiastolic blood pressure
Tirzepatide → Diastolic blood pressure
Tirzepatide → Diastolic blood pressure
Evidence Intelligence™
- EvidenceScore™
- 77
- Strong
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 3 estudios
Add to Evidence TrackerGastrointestinal disorders incidence
Tirzepatide → Gastrointestinal disorders incidence
Tirzepatide → Gastrointestinal disorders incidence
Evidence Intelligence™
- EvidenceScore™
- 77
- Strong
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 4 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 96
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 14 estudios
Add to Evidence TrackerIncidence of hypoglycaemia
Tirzepatide → Incidence of hypoglycaemia
Tirzepatide → Incidence of hypoglycaemia
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 77
- Strong
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 3 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 78
- Strong
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 3 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 77
- Strong
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 4 estudios
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Weight loss of -23.3 kg in early responders indicates significant effectiveness.
- Blood pressure decreased by -9.8 mmHg in early responders, showing cardiovascular benefits.
- Nausea reported in 19.6% of early responders, highlighting potential side effects.
A quién se aplica
- Adults with obesity or overweight.
- Individuals at risk for cardiometabolic diseases.
Tener en Cuenta
- Results may not apply to populations outside the study demographics.
- Long-term efficacy and safety of Tirzepatide remain to be fully established.
- Adverse effects were noted, which may affect treatment adherence.
Entre Líneas
- Limited generalizability due to specific participant characteristics.
- Potential for unmeasured confounding factors.
- Short duration of follow-up may not capture long-term effects.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 96
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 14 estudios
View evidenceMedications
GLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 92
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 13 estudios
View evidenceMedications
GLP-1 Receptor Agonists → Blood Pressure
Medications
Evidence Intelligence™
- EvidenceScore™
- 77
- Strong
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 3 estudios
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
14 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
14 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
13 studies
outcome_hubMeasures Body Weight as a key outcome.
Blood Pressure Evidence Hub
All studies measuring Blood Pressure
3 studies
outcome_hubMeasures Blood Pressure as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Tirzepatide and HbA1c
Intervention: TirzepatideOutcome: HbA1c
14 results
All studies on Tirzepatide and Body weight
Intervention: TirzepatideOutcome: Body weight
13 results
All studies on Tirzepatide
Intervention: Tirzepatide
14 results
All studies measuring HbA1c
Outcome: HbA1c
14 results
All studies measuring Body weight
Outcome: Body weight
13 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do GLP-1 Receptor Agonists lower HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appear to lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 83.5 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 45 supporting studies with consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may affect body weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 82.9 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 43 supporting studies with consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists affect body mass index?
Strong Evidence
GLP-1 Receptor Agonists may affect body mass index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Strong | EvidenceScore™ 77.9 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 20 supporting studies with consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists affect gastrointestinal adverse events?
Strong Evidence
Current evidence does not show a clear effect of GLP-1 Receptor Agonists on gastrointestinal adverse events.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Gastrointestinal disorders incidence
EvidenceScore™ Strong | EvidenceScore™ 77.3 | neutral | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 12 supporting studies and existing graph evidence signals.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Tirzepatide may prevent type 2 diabetes in adults with obesity and prediabetesHigh-protein diet may reduce cardiometabolic risks in diabetes patientsHibiscus extract may improve kidney function in type 2 diabetesPhone-delivered diabetes education improves self-care behaviorsTirzepatide improves glycemic control in early-onset type 2 diabetes
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.